Controlled Substances

Iowa House Amendment H-8327 to HF 2748 Clarifies Hemp Product Definitions and Inhalable Hemp Ban

Iowa House amendment H‑8327 to HF 2748, filed on 07 April 2026, would redefine “consumable hemp product” to exclude inhalable hemp products and newly defined “minimally processed hemp”, while classifying compliant hemp and minimally processed hemp as agricultural commodities and farm crops.[^1^](https://www.legis.iowa.gov/legislation/BillBook?ga=91&ba=H8327#:~:text=Sec.%5C_\_\_\_.Section204.2,Minimallyprocessedhempasdefinedinsection204A.2.) If enacted, the change would leave Iowa’s existing criminal ban on inhalable hemp products intact under §204.14A but give hemp growers and processors clearer boundaries between prohibited inhalable products, regulated consumable hemp products, and raw or minimally processed hemp treated as agricultural commodities.[^2^](https://www.legis.iowa.gov/docs/code/2026/204.14A.pdf)

10 Apr 2026, 15:32legis.iowa.govUnited States

Netherlands Proposes Listing Nitazenes Group and Isotonitazepyne Under Opium Act

The Netherlands has proposed a decree to add the nitazenes group of synthetic opioids to list IA of the Opium Act and to schedule the highly potent opioid isotonitazepyne on list I, with an explanatory memorandum now before Parliament (dossier 24077/559). If adopted, this will significantly tighten controls on emerging synthetic opioids, requiring additional Opium Act exemptions and permits for laboratories, healthcare institutions, and other operators handling controlled opioids in the Netherlands.

10 Apr 2026, 13:02zoek.officielebekendmakingen.nlNetherlands

Netherlands AMvB To Add Isotonitazepyne and Nitazene Opioid Group to Opium Act Lists I and IA

In April 2026, the Netherlands published the text of an order-in-council (AMvB) that will amend the Opium Act by adding the synthetic opioid isotonitazepyne to List I and introducing a structurally defined “benzimidazole opioids (nitazenes)” substance group in List IA. Once the decree is published in the Staatsblad, isotonitazepyne and a broad set of nitazene analogues will become fully controlled under Dutch narcotics law, so manufacturers, laboratories and healthcare providers need to treat any handling or trade as tightly regulated and prepare compliance processes accordingly.

10 Apr 2026, 12:58zoek.officielebekendmakingen.nlNetherlands

District of Columbia Council Introduces Medical Cannabis Beverage Product Amendment Act of 2026

DC introduced legislation in April 2026 to allow alcohol manufacturers to produce non-alcoholic medical cannabis beverages and permit the import of THC-free cannabinoids. This creates new contract manufacturing opportunities and formalizes supply chain requirements, signaling a shift toward integrated production and stricter oversight of cannabinoid inputs.

9 Apr 2026, 14:22lims.dccouncil.govUnited States

Washington Pharmacy Commission Opens Rulemaking On Animal Euthanasia Training Program Guidelines

Washington is transitioning animal euthanasia training guidelines into enforceable regulations to standardize the authorization of personnel handling controlled substances. Affected agencies should anticipate mandatory training criteria and stricter compliance oversight for chemical capture and euthanasia programs.

9 Apr 2026, 14:19content.govdelivery.comUnited States

Missouri House Schedules Nuclear Clean Power, Paint Recycling And Xylazine Bills For Floor Consideration

Missouri advances legislation establishing a statewide paint recycling program, nuclear energy cost-recovery, and stricter controls on xylazine (April 2026). Companies should prepare for new producer responsibility obligations in the coatings sector and evolving regulatory frameworks for clean energy and controlled substances.

9 Apr 2026, 10:23house.mo.govUnited States

US DEA Finalises List I Designation of P2P Methyl Glycidic Acid and Its Esters

The US DEA has designated P2P methyl glycidic acid and its esters as List I chemicals under the Controlled Substances Act, effective May 4, 2026. Impacted operators must secure DEA registrations and implement rigorous compliance controls, as the lack of a concentration threshold brings all mixtures containing these substances into scope.

6 Apr 2026, 16:07federalregister.govUnited States

South Carolina Bill H5485 Proposes Adding Tianeptine to Schedule I Controlled Substances

South Carolina has introduced legislation to classify tianeptine as a Schedule I controlled substance, effectively banning its manufacture, distribution, and possession. Businesses in the pharmaceutical or supplement sectors must prepare for immediate market exit or strict criminal regulatory controls upon the bill's enactment.

5 Apr 2026, 18:52scstatehouse.govUnited States

Alabama Legislature Urges Schedule I Review of Synthetic Opioid Cychlorphine

Alabama's House has adopted a resolution urging the immediate Schedule I classification of the synthetic opioid Cychlorphine. This signals imminent state-level restrictions and reflects a broader trend of rapid legislative responses to novel synthetic substances.

5 Apr 2026, 05:35alison.legislature.state.al.usUnited StatesAlbania

England: Environment Agency Raises Waste Exemption Charges Following CPI Uplift

The Environment Agency has increased waste exemption registration and compliance charges in England effective 1 April 2026, following a CPI-linked inflationary adjustment. Businesses should update operational budgets and pricing models to account for higher costs associated with new or renewed waste management exemptions.

4 Apr 2026, 11:01gov.ukUnited Kingdom

US DEA Seeks Comment on MDMA Importer Registration for Fisher Clinical Services, Inc.

The US DEA is reviewing an application from Fisher Clinical Services to import MDMA for clinical trial use, with a public comment deadline of May 1, 2026. This move reflects the ongoing regulatory pathway for psychedelic substances in medical research, signaling continued federal oversight of supply chains for restricted compounds.

4 Apr 2026, 10:55federalregister.govUnited States

Iowa Legislative Subcommittee Schedules 1 April 2026 Hearing on HF 978 (Psilocybin Bill)

Iowa is advancing HF 978 to establish a regulated medical psilocybin framework, with licensing for production and therapy potentially starting in July 2026. This development signals a shift toward a legal, state-controlled market for psychedelics, requiring rigorous compliance with production, testing, and inventory standards.

3 Apr 2026, 18:33legis.iowa.govUnited States

US DEA Invites Comments on Importer Registration Application for Research Triangle Institute

The US DEA is reviewing an application from Research Triangle Institute to import Schedule I and II controlled substances for research, with a comment deadline of May 1, 2026. This proceeding underscores strict federal control over the import of restricted substances and offers existing bulk manufacturers an opportunity to contest the registration.

2 Apr 2026, 17:06federalregister.govUnited States

US House Introduces HERO Act (H.R. 7994) on Opioid Overdose Reversal Drugs in Schools

The US House introduced the HERO Act in March 2026 to fund opioid overdose reversal drugs and emergency response planning in schools. Educational institutions and pharmaceutical suppliers should prepare for increased demand and new mandatory reporting obligations to national overdose surveillance systems.

2 Apr 2026, 11:07govinfo.govUnited States

Netherlands Draft Opium Act Decree to Add Nitazenes Group to List IA and Isotonitazepyne to List I

The Netherlands has proposed adding the nitazene opioid group and isotonitazepyne to the Opium Act's controlled substance lists. This shift toward group-based scheduling broadens enforcement reach and requires immediate compliance reviews for entities handling synthetic opioids or related chemical precursors.

2 Apr 2026, 10:18open.overheid.nlNetherlands

Netherlands Court of Appeal Confirms Nitrous Oxide Conviction Without Chemical Test

The Dutch Court of Appeal has ruled that criminal convictions for illegal nitrous oxide trade can be secured through labeling and circumstantial evidence, bypassing the need for laboratory chemical analysis. This precedent lowers the evidentiary threshold for authorities, significantly increasing enforcement and litigation risks for entities involved in the distribution of controlled substances.

2 Apr 2026, 09:46uitspraken.rechtspraak.nlNetherlands

EU Council Working Party on Customs Union To Examine Drug Precursors Monitoring And Control Regulation Proposal

EU Council negotiations on the recast Drug Precursors Monitoring and Control Regulation are advancing with a detailed article-by-article review scheduled for April 2026. This signals a move toward a unified and potentially more stringent oversight framework for the trade and monitoring of precursor chemicals across the EU.

2 Apr 2026, 09:23data.consilium.europa.euEuropean Union

Missouri House Advances Bill Adding Xylazine to Schedule III Controlled Substances

Missouri is advancing legislation to schedule xylazine as a controlled substance and tighten permits for invasive plants, with key changes expected by August 2026. Businesses must prepare for increased regulatory oversight on veterinary drugs and stricter affidavit requirements for seed and plant sales.

2 Apr 2026, 08:43house.mo.govUnited States

Latvian Saeima Adopts Second Reading Of Pharmacy Law Amendments And Sets Third-Reading Deadline

Latvia has advanced amendments to its Pharmacy Law through the second reading, setting a deadline for final proposals in April 2026. Companies must prepare for potential shifts in pharmaceutical distribution and precursor controls as the legislation nears final adoption.

2 Apr 2026, 07:55titania.saeima.lvLatvia

Denmark Adopts New Controlled Substances Order (BEK 405 of 2026)

Denmark’s updated Executive Order on euphoriant substances (BEK 405) entered into force on 29 March 2026, replacing the 2021 regulatory framework. Businesses must audit portfolios against updated substance lists and ensure rigorous compliance with tracking, reporting, and security obligations for controlled chemicals and hemp-derived products.

1 Apr 2026, 14:32retsinformation.dkDenmark